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| INTRODUCTION

Multidrug resistance protein (MRP) 4 is a member of the MRP/ATP
Binding Cassette subfamily C (ABCC) subfamily of ATP-binding cassette transporters, which are capable of pumping several molecules including drugs out to the cell.
1 MRP4 expression and function have been associated with drug resistance. 2 Interestingly, MRP4
plays an important role in platelet function, an impaired cAMP homeostasis and platelet activation were reported in MRP4-deficent mice. 3, 4 MRP4 inhibition showed a reduced platelet function and thrombus formation. 5 Recently, we demonstrated that aspirin modulates MRP4 expression through a PPARα-dependent mechanism 6 and that its upregulation is an adaptive response to limit intracellular toxicity. 7 Aspirin MRP4-induced over-expression correlates with high onaspirin treatment residual platelet reactivity, that is due in part to incomplete COX-1 inhibition, and in part to COX-1-independent mechanisms. 8 The PLATO trial group recently suggested a phenomenon called platelet adaptome, that originating in megakaryocytes given their diversity and ability to respond at the molecular level to pharmacological inhibition. Recently, Kida et al. found that the nuclear receptor PPARα is regulated by miR-21 in human liver cells.
11
As miRNAs are key regulators of gene expression in both healthy and pathological conditions, [12] [13] [14] these data prompt us to investigate whether miRNAs play an important role in platelet function.
In this study, we verified if aspirin treatment, both in vitro and in vivo, is involved to regulate PPARα and MRP4 expression.
| METHODS
| Cell culture
DAMI cell line (human megakaryoblastic culture) was maintained in Roswell Park Memorial Institute (RPMI) supplemented with 10%
heat-inactivated fetal bovine serum, 100 U/mL of penicillin G sodium, 100 μg/mL streptomycin sulphate, and 20 mmol/L l-glutamine in a humidified atmosphere with 5% CO 2 at 37°C. 15 The A FAM-labeled negative control LNA oligonucleotide (AM 17012; ThermoFisher Scientific) was transfected in the same conditions to measure transfection efficiency that was estimated as 90%.
| miRNA Transfection in DAMI cells
Cells, after 24 hours of transfection, were treated with or without aspirin (50 μmol/L) for 48 hours with the same procedure.
| Purification of human hematopoietic progenitor cell
Peripheral blood (PB) was obtained from male donors after written informed consent. Low density mononuclear cells (MNCs) (in average 0.1%) were isolated by Ficoll-Hypaque (Lympholyte CL5020;
Cederlane Lab, Burlington, Canada) density gradient (1.077 g/mL)
centrifugation at 600 g for 30 minutes, RT. MiniMACS isolation system (Milteny, Bergisch, Gladbach, Germany) was used to purify 
Essentials
• Aspirin reduces miR-21 expression that downregulates PPARα expression.
• To evaluate multidrug resistance protein 4 (MRP4), PPARα, and miR-21 expression, after aspirin treatment.
• Inverse relationship between miR-21 and MRP4 expression in aspirin-treated platelets.
• Platelet miR-21 may be a useful biomarker to identify patients less sensitive to aspirin action.
Cultures were maintained for 14 days at 37°C in a fully humidified atmosphere of 5% CO 2 , 5% O 2 , and 90% N 2 . megakaryocytes were collected, counted, and analyzed for viability, morphology, and phenotype at different days of culture (6, 9, 12, and 14) in order to control the differentiation stage. 16 At day 14 megakaryocytes collected were processed for RNA extraction.
Platelet-like particles were obtained by centrifugation at 800 g for 10 minutes at room temperature and processed for RNA extraction.
| Patients
To evaluated platelet miR-21 expression after aspirin treatment, we enrolled:
1. Ten healthy Caucasian volunteers taking aspirin 300 mg/d for 15 days and we performed analysis after 1 day of pill treatment (T1), and subsequently after 7 (T7) and 15 days (T15).
These volunteers were previously analyzed for MRP4 expression. Volunteers are subjects obtained from our transfusion center who had no risk factors and had no taken any medications.
To evaluate platelet MRP4 and miR-21 expression after chronic aspirin treatment, we enrolled:
1. Twenty-five aspirin free patients (control population);
2. Twenty-five aspirin chronic treated patients (100 mg/d), aspirin exposure >2 months (aspirin-treated patients >2 months).
In patients under chronic treatment, the compliance was assessed both by interview and as arachidonic acid-induced platelet aggregation (0.75 mmol/L) < 10%. 17 In our study, were excluded all those patients with cardiovascular diseases including: Ischemic Heart Disease (IHD), cerebrovascular disease or transient ischemic attack, established peripheral vascular disease, and class III to IV heart failure, in the previous 15 days.
Informed written consent was obtained from each healthy volunteer and patient.
All clinical parameters of the study population are presented in Table 1 . The study was approved by the Hospital Ethics Committee.
| Platelets preparation and isolation
Platelet preparation was performed according to Pulcinelli et al. 
| RT-Q-PCR for miRNA analysis
For the detection of mature miR-21, it has been made a reversetranscriptase reaction in which 10 ng of total RNA were reversely transcribed using the High Capacity cDNA Archive Kit (ThermoFisher Scientific).
Real-Time PCR was performed using a miRNA-specific Taq-Man Assay (ThermoFisher Scientific) in an Applied Biosystems 7900HT
Sequence Detection System (Life Technologies). U6 snRNA was used for normalization. The program of amplification used was the same as for MRP4 analysis.
| Protein extraction and Western blot
To analyze the MRP4 protein, platelets were washed twice with platelet washing buffer, collected and centrifuged at 7000 g for 3 minutes.
Platelet and cell pellets were then resuspended in lysis buffer
and protein extracts were analyzed by Western Blot. 6 The National Institutes of Health ImageG analyzer program was performed for densitometric analysis.
| Statistics
Data are presented as mean ± SD. The level of significance was determined by paired, 2-tailed Student's t test and, for differences among groups, by using one-way ANOVA and Bonferroni post-hoc test (Software 3.6 of KaleidaGraph, Synergy Software, Reading, PA, USA).
Results were considered statistically significant when P value was less than .05.
| RESULTS
| Aspirin-dependent mir-21 downregulation is associated with MRP4 and PPARα upregulation in DAMI culture
Aspirin dependent miR-21 expression was investigated in in vitro experiments. To verify if miR-21 was regulated after aspirin treatment, we treated DAMI cells with aspirin 50 μmol/L for 48 hours, a concentration and a time required to upregulate MRP4 expression through a mechanism PPARα dependent, as previously reported. 6 Real-time PCR analysis showed that, in cells treated with aspirin, the expression of miR-21 was inhibited by 46% compared to control cells ( Figure 1A ). This miR-21 downregulation was associated with a MRP4 and PPARα mRNA upregulation ( Figure 1B ,C).
| MiR-21 downregulates PPARα and MRP4 in DAMI cells
In To further confirm such correlation we also analyzed MRP4
protein expression through Western blot. Figure 3D To further confirm such correlation we also studied MRP4
protein expression, Figure 4D shows densitometric analysis of platelet MRP4 and confirms data previously shown. MiR-21 
| MiR-21 is modulated by aspirin in human megakaryocytes
In order to demonstrate that aspirin modulates miR-21 expression in human megakaryocytes and that there is a correspondence with MRP4 upregulation, we studied the aspirin effect in human peripheral blood progenitor cell cultures during maturation along the megakaryocytes lineage. In our previous studies we optimized an in vitro unlineage serum-free liquid culture system for a virtually "pure" and complete megakaryocytes differentiation, including pro-platelets and platelet-like particles' formation. 16 Aspirin (50 mol/L) was added at day 6 to differentiating megakaryocytes (when most cells are precursors, see Guerriero et al. 16 ) and this treatment was continued for 4 days. 6 As shown in Figure 5 a statistically significant reduction of miR-21 expression was evident both in differentiating megakaryocytes treated with aspirin and collected at day 12 (inhibition: 76 ± 5%) ( Figure 5A ) and in derived platelet-like particles on day 14 of differentiation (inhibition:
30 ± 3%) ( Figure 5C ).
Interestingly MRP4 mRNA is increasingly expressed in both aspirin-treated megakaryocytes during days 12 of maturation (2.0 ± 0.3 fold increase) ( Figure 5B), and in the newly formed platelets (1.6 ± 0.05 fold increase) ( Figure 5D ) as compared with control cultures.
These data confirm that miR-21 enhancement and MRP4 decrease aspirin dependent is evident in human megakaryocytes and in derived platelets obtained at the end of megakaryocytes culture.
| MiR-21 downregulates MRP4 in human platelets
To investigate whether aspirin could regulate miR-21 expression even after in vivo administration and to verify the correlation between MRP4 and miR-21, we explored miR-21 expression in platelets obtained from volunteers after aspirin treatment which have aspirin induced MRP4 over-expression, as previously shown. 6, 8 In 300 mg/d aspirin-treated volunteers that show MRP4 upregulation after 15 days of treatment, miR-21 expression is downregulated in a statistically significant manner after 7 and 15 days (inhibition: 45 ± 17% and 47 ± 19%, respectively) ( Figure 6A ).
This reverse relationship between miR-21 and MRP4 expression was also found in platelets of volunteers after 100 mg/d aspirin administration who exhibited a significant MRP4 upregulation after 8 weeks and miR-21 downregulation (inhibition: 71 ± 23%), that is statistically significant also after 4 weeks from the start of treatment (inhibition: 54 ± 25%) ( Figure 6B ).
A similar reverse relationship was found in aspirin-treated patients, since they had a significant MRP4 increase (2.07 ± 0.22 fold increase) and a significant miR-21 decrease (inhibition: 49 ± 18%), compared to the control population ( Figure 6C,D) . 
| CONCLUSION
Previously, we demonstrated that platelet MRP4 overexpression reduces aspirin-induced COX-1 inhibition for its ability to extrude this drug from platelets. 20 We also demonstrated that both in vitro and in vivo aspirin treatment induces MRP4 upregulation through the activation of nuclear receptor PPARα. In vitro regulation of miR-21 by aspirin was previously demonstrated in epithelial cancer cells. 10 It was demonstrated that the Moreover, we report that patients under chronic aspirin treatment express low miR-21 levels compared to a control population.
It is now established that mRNA transcripts expression are the results of a transcriptional and posttranscriptional regulation by miRNAs. 22, 23 Therefore, multiple evidences show that megakaryocytes transfer mRNA and miRNA to circulating platelets and that this transferred genetic code changes in different diseases. 24 On the basis of our study, we can strongly suggest that the reduction of miR-21 in platelets is dependent on aspirin action in megakaryocytes and subsequently transferred to the platelets, as previously demonstrated. 6 Platelets from patients under chronic aspirin treatment with high levels of MRP4 have increased rates of high on-aspirin treatment residual platelet reactivity. Moreover, platelets from patients with osteoarthritis, who are regular NSAID users, have an increased platelet reactivity due to an higher expression of MRP4. 25 Importantly, emerging studies support an association between high on-aspirin treatment residual platelet reactivity and adverse clinical outcomes in patients with cardiovascular and cerebrovascular disease. [26] [27] [28] [29] A recent study has shown that targeted inhibition of miR-21 maturation with designed RNA-binding proteins is very important useful in the oncogenic treatment of tumors, 30 suggesting that this treatment can also be translated in other situations.
In conclusion, in our study, we have demonstrated that miR-21
downregulation plays an important role in the modulation of MRP4 over-expression and that its enhancement can abolish aspirininduced MRP4 over-expression. 
